Browsing: Health

FDA declined to accept Moderna’s mRNA-1010 flu vaccine application for review, citing trial comparator concerns, and Moderna requested a Type A meeting with FDA.

Nash County warns of possible measles exposure at UNC Health Nash, ER after an unvaccinated child visited Jan. 27; public urged to check MMR status Call ahead!

FDA classified a Class II recall for 80,000+ McCafé decaf K-Cups after a labeling error. Some pods may contain caffeine for Keurig.

HHS restored nearly $2 billion in mental health and substance use grants after abrupt cancellations raised concern among providers states and lawmakers today.

Epic Systems filed a federal lawsuit alleging a health data network improperly accessed nearly 300000 patient records through national medical exchange systems.

Scientists studying SuperAgers report preserved brain structure and cellular health help explain why some seniors keep strong memory well into their 80s.

Implanted living skin developed by Japanese scientists glows to signal internal health changes, showing how biological tissue can function as a sensor.

A Stanford study shows inhibiting an aging enzyme regenerates cartilage in animal models and human tissue, advancing osteoarthritis research worldwide.

Amazon Pharmacy is accepting US prescriptions for the Wegovy pill, with eligible insurance pricing and nationwide home delivery options.

INDIANAPOLIS, December 12, 2025: Eli Lilly and Co. announced that its next-generation obesity drug, retatrutide, achieved significant weight loss and reduced knee pain in a late-stage Phase 3 trial, underscoring its potential as a major advance in obesity and osteoarthritis treatment. The TRIUMPH-4 study evaluated retatrutide, a triple-hormone receptor agonist that activates GLP-1, GIP, and glucagon pathways, in adults with obesity and knee osteoarthritis. Participants receiving the highest dose of the drug lost an average of 28.7 percent of their body weight after 68 weeks of treatment, equivalent to approximately 71 pounds. Those receiving placebo lost an average of 2.1 percent…